Machine Engineering, Inc, 3244 Ricky Dr, Jacksonville, FL 32223, US

Symbinas Pharmaceuticals Inc. is an early-stage biopharmaceutical company based in St Johns, FL, dedicated to developing innovative therapies for concussion and traumatic brain injuries (TBI). With a mission to positively impact the lives of patients and families affected by TBI, Symbinas is developing two investigational drugs, SMB-603 and SMB-710, to treat TBI and address the global medical crisis of concussion and TBI, which affects over 50 million people annually and incurs an annual cost of over $400 billion worldwide. Led by Founder, Chairman, and CEO, Dr. Hardesh Garg, an internationally-recognized expert in stem cell and regenerative medicine, Symbinas Pharmaceuticals Inc. incorporates unconventional approaches and strong partnerships with industry leaders, scientists, physicians, and organizations to achieve positive outcomes for TBI patients and their families. Their drug candidates aim to improve mitochondrial function and inhibit neuro-inflammation, treating the underlying cellular causes of concussions and TBI, rather than simply managing symptoms, and potentially providing long-term treatment for complications such as anxiety, PTSD, insomnia, dementia, agitation, and even Alzheimer's and Parkinson's disease.Generated from the website